Millions of people deal with acne, but those who suffer from cystic acne know how difficult it is to treat compared to ordinary pimples. Cystic acne is a severe form of acne that results in large, pus ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis ...

Please provide your email address to receive an email when new articles are posted on . Denifanstat, a fatty acid synthase inhibitor, was effective in the treatment of moderate to severe acne vulgaris ...

Treatment with a 1726-nm laser resulted in sustained efficacy for moderate-to-severe acne, with more than 90% of treated patients achieving at least a 50% reduction in inflammatory lesions at 52 weeks ...

Thanks For Watching Subscribe to become a part of #HealthApta SUBSCRIBE for awesome videos every day!: Like, Comment, Share and Enjoy the videos. Colorado school shooting came hours after parents ...

Hydrocolloid patches help heal pimples by absorbing fluid and keeping bacteria out. Hydrocolloid patches do not work on blackheads, whiteheads, or cystic acne. Some hydrocolloid patches contain ...

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More ...

Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...